CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
505.85BKRW365.12M · vs all stocks (USD)
Revenue (TTM)
239.07BKRW172.56M · vs all stocks (USD)
Profit Margin
-0.34%Beta
1.16xvs all stocks
52-Week Change
-31.74%vs all stocks
Market Capitalization
505.85BKRW365.12M · vs all stocks (USD)
Enterprise Value
477.40BKRW344.59M · vs all stocks (USD)
Price to Sales (TTM)
2.12xPrice to Book (MRQ)
1.79xEnterprise to Revenue
2.00xEnterprise to EBITDA
34.08xGross Margin
42.25%Profit Margin
-0.34%Operating Margin
-12.57%Return on Assets (TTM)
0.48%Return on Equity (TTM)
-0.28%Revenue (TTM)
239.07BKRW172.56M · vs all stocks (USD)
Revenue per Share (TTM)
4.83KKRWUpdated Sep 19, 2026Quarterly Revenue Growth
9.00%Gross Profit (TTM)
102.10BKRW73.70M · vs all stocks (USD)
EBITDA (TTM)
25.41BKRW18.34M · vs all stocks (USD)
Net Income (TTM)
-1.19BKRW-856.62K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
8.99%Operating Cash Flow (TTM)
17.57BKRW12.68M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
7.29BKRW5.26M · vs all stocks (USD)
5-Year Average Dividend Yield
1.15%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
752.64MKRWFY2025 · Dec 31, 2025Revenue
234.68BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
132.01BKRWFY2025 · Dec 31, 2025Gross Profit
102.67BKRWFY2025 · Dec 31, 2025Operating Income
14.26BKRW10.29M · vs all stocks (USD)
Pre-tax Income
8.45BKRWFY2025 · Dec 31, 2025Income Tax Expense
62.48MKRWFY2025 · Dec 31, 2025Net Income
8.39BKRWFY2025 · Dec 31, 2025EBIT
11.14BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
25.41BKRWFY2025 · Dec 31, 2025Research & Development
10.44BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
28.54BKRWFY2025 · Dec 31, 2025Other Operating Expenses
-1.13BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
767.26MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
2.69BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
8.39BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
435.95MKRWFY2025 · Dec 31, 2025Operating Cash Flow
3.02BKRWFY2025 · Dec 31, 2025Free Cash Flow
-455.21MKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
47.43BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
8.39BKRWFY2025 · Dec 31, 2025Other Non-cash Items
1.92BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.12BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.17BKRWFY2025 · Dec 31, 2025Capital Expenditures
-3.48BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-513.09MKRWFY2025 · Dec 31, 2025Purchase of Investments
-121.68BKRWFY2025 · Dec 31, 2025Sale of Investments
110.96BKRWFY2025 · Dec 31, 2025Other Investing Activity
10.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-14.19BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
11.88BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-6.75BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
5.13BKRWFY2025 · Dec 31, 2025Shares Outstanding
51.71MSharesUpdated Sep 19, 2026Float Shares
34.78MSharesUpdated Sep 19, 2026% Held by Insiders
31.99%vs all stocks
% Held by Institutions
2.56%vs all stocks
Total Cash (MRQ)
72.31BKRW52.19M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.37KKRWUpdated Sep 19, 2026Total Debt (MRQ)
53.28BKRW38.46M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1916xCurrent Ratio (MRQ)
2.86xBook Value per Share (MRQ)
5.27KKRWUpdated Sep 19, 2026Total Assets
352.47BKRW254.41M · vs all stocks (USD)
Total Current Assets
206.74BKRWFY2025 · Dec 31, 2025Total Liabilities
81.74BKRWFY2025 · Dec 31, 2025Total Non-current Assets
145.73BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
14.83BKRWFY2025 · Dec 31, 2025Total Current Liabilities
66.91BKRWFY2025 · Dec 31, 2025Cash
47.43BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
47.43BKRWFY2025 · Dec 31, 2025Other Short-term Investments
24.07BKRWFY2025 · Dec 31, 2025Accounts Receivable
72.54BKRWFY2025 · Dec 31, 2025Inventory
58.48BKRWFY2025 · Dec 31, 2025Accounts Payable
7.10BKRWFY2025 · Dec 31, 2025Short-term Debt
44.36BKRWFY2025 · Dec 31, 2025Other Current Liabilities
2.77BKRWFY2025 · Dec 31, 2025Long-term Debt
11.50BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
210.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
26.49BKRWFY2025 · Dec 31, 2025Retained Earnings
50.77BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
270.73BKRW195.41M · vs all stocks (USD)
Treasury Stock
8.73BKRWFY2025 · Dec 31, 202552-Week Low
6.31KKRWUpdated Sep 19, 202652-Week High
15.90KKRWUpdated Sep 19, 202652-Week Change
-31.74%vs all stocks
Beta
1.16xvs all stocks
50-Day MA
8.74KKRWUpdated Sep 19, 2026200-Day MA
10.88KKRWUpdated Sep 19, 2026Avg 10-Day Volume
376.90KSharesUpdated Sep 19, 2026Avg 30-Day Volume
662.45KSharesUpdated Sep 19, 2026Diluted EPS (TTM)
172.00KRWUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.42Profit Margin: -0.00
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.81
Altman Z-Score 5.16: safe zoneNotable
Altman Z-Score: 5.16
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
C4 Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Qinghai Spring Medicinal Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orchestra BioMed Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule